GLC determination of plasma drug levels after oral administration of clorazepate potassium salts.
Plasma nordiazepam levels resulting from the oral administration of clorazepate potassium salts were determined by a sensitive GLC assay. Nordiazepam and the internal standard (diazepam) were selectively extracted into ether at pH 9.2, hydrolyzed to their respective benzophenones, and quantified by electron-capture detection. The assay was used in a comparative bioavailability study of single equimolar oral doses of monopotassium and dipotassium salts of clorazepate in dogs. Both clorazepate salts were rapidly absorbed and exhibited mean peak total drug levels after 1 hr. Clorazepate levels accounted for about 50% of the total drug levels present. No statistical difference in the plasma drug levels of clorazepate mono- and dipotassium salts and the metabolite was found in dogs.
D000284:Administration, Oral; D000818:Animals; D014151:Anti-Anxiety Agents / Q000097:blood*; D001682:Biological Availability; D002849:Chromatography, Gas; D003009:Clorazepate Dipotassium / Q000008:administration & dosage / Q000097:blood*; D003975:Diazepam / Q000031:analogs & derivatives / Q000097:blood; D004285:Dogs; D005260:Female; D013997:Time Factors
D014151:Anti-Anxiety Agents; D003009:Clorazepate Dipotassium; D003975:Diazepam